Pharmaceutical

Sanofi backs development of Graviton’s treatments for serious diseases

Graviton Bioscience has secured a strategic investment from Sanofi to propel the development of ROCK2 inhibitors for serious diseases.

Feb 2, 2024 - 18:00
Sanofi backs development of Graviton’s treatments for serious diseases
Graviton Bioscience has secured a strategic investment from Sanofi to propel the development of ROCK2 inhibitors for serious diseases.
Read the original article

Tags:

Previous Article

Biosyngen’s liver cancer therapy receives fast track designation

Next Article

Tyra Biosciences’ TYRA-300 gains FDA rare paediatric disease status

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bupa is leveraging its unique position to develop IoT and AI features

Bupa is leveraging its unique position to develop IoT a...

Jan 17, 2024

Sensorion raises $16m for gene therapies to treat deafness

Sensorion raises $16m for gene therapies to treat deafness

Apr 9, 2024

STAT+: Biotech and pharma execs wrestle with the ‘nightmare’ of developing digital biomarkers

STAT+: Biotech and pharma execs wrestle with the ‘night...

May 17, 2023